Sana Biotechnology Cuts 15% of Workforce and Shuts Heart Failure Program to Focus on Clinical Trials
Sana Biotechnology, a Seattle-based cell and gene therapy company, is cutting 15% of its workforce by the end of the year and shutting down a heart failure program as it shifts focus to clinical-stage development. Despite laying off 75 to 80 employees, Sana has sufficient cash runway to last into 2025 after raising $587 million in its 2021 IPO.